In the last trading session, 32.93 million Pfizer Inc (NYSE:PFE) shares changed hands as the company’s beta touched 0.63. With the company’s per share price at $26.31 changed hands at $0.26 or 1.00% during last session, the market valuation stood at $149.11B. PFE’s last price was a discount, traded about -19.88% off its 52-week high of $31.54. The share price had its 52-week low at $24.48, which suggests the last value was 6.96% up since then. When we look at Pfizer Inc’s average trading volume, we note the 10-day average is 40.62 million shares, with the 3-month average coming to 40.37 million.
Analysts gave the Pfizer Inc (PFE) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.29. If we narrow down to specifics, the data shows that 1 out of 16 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 7 recommended PFE as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Pfizer Inc’s EPS for the current quarter is expected to be 0.71.
Pfizer Inc (NYSE:PFE) trade information
Instantly PFE was in green as seen at the end of in last trading. With action 1.23%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -0.83%, with the 5-day performance at 1.23% in the green. However, in the 30-day time frame, Pfizer Inc (NYSE:PFE) is 3.06% up. Looking at the short shares, we see there were 94.96 million shares sold at short interest cover period of 2.34 days.
The consensus price target for the stock as assigned by Wall Street analysts is 32, meaning bulls need an upside of 17.78% from its current market value. According to analyst projections, PFE’s forecast low is 32 with 33 as the target high. To hit the forecast high, the stock’s price needs a -25.43% plunge from its current level, while the stock would need to soar -21.63% for it to hit the projected low.
Pfizer Inc (PFE) estimates and forecasts
Year-over-year growth is forecast to reach -1.08% down from the last financial year.
Consensus estimates given by 12 financial analysts project the company’s revenue in the current quarter to hit an average of 14.43B. 11 analysts are of the opinion that Pfizer Inc’s revenue for the current quarter will be 13.54B. The company’s revenue for the corresponding quarters a year ago was 14.88B and 13.28B respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -3.04%. The estimates for the next quarter sales put growth at 1.92%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -13.25%. The 2025 estimates are for Pfizer Inc earnings to decrease by -4.78%, but the outlook for the next 5-year period is at -0.88% per year.
PFE Dividends
Pfizer Inc is expected to release its next quarterly earnings report on 2025-Feb-03. The 6.42% annual yield figure for the share gives it an annual dividend of 1.69. It is important to note, however, that the 6.42% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision. During the past 5 years, the average dividend yield was 4.4 per year.
Pfizer Inc (NYSE:PFE)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.06% of Pfizer Inc shares while 67.47% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 67.51%. There are 67.47% institutions holding the Pfizer Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 9.0402% of the shares, roughly 511.4 million PFE shares worth $14.31 billion.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.5018% or 424.38 million shares worth $11.87 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund . With 177.62 shares estimated at $4.67 billion under it, the former controlled 3.13% of total outstanding shares. On the other hand, Vanguard 500 Index Fund held about 2.70% of the shares, roughly 153.4 shares worth around $4.04 billion.